Table 1.
Characteristics of limited-stage SCLC cohort and multivariate model for predictors of the use of immunotherapy.
| Variable | Immunotherapy | Multivariate OR (95% CI)** | p-value | |
|---|---|---|---|---|
| No (n = 50,429) | Yes (n = 98) | |||
| Age | ||||
| <70 (ref) | 28,075 (55.6%) | 70 (71.4%) | 1 | |
| >70 | 22,452 (44.4%) | 28 (28.6%) | 0.513 (0.331–0.797) | 0.003 |
| Sex | ||||
| Male (ref) | 21,904 (43.4%) | 42 (42.9%) | 1 | |
| Female | 38,623 (56.6%) | 56 (57.1%) | 1.012 (0.678–1.511) | 0.954 |
| Race | ||||
| White (ref) | 46,927 (92.9%) | 91 (92.9%) | 1 | |
| Black | 3600 (7.1%) | 7 (7.1%) | 0.920 (0.425–1.992) | 0.833 |
| Charlson/Deyo score | ||||
| 0–1 (ref) | 52,587 (84.3%) | 89 (90.8%) | 1 | |
| 2–3 | 7940 (15.7%) | 9 (9.2%) | 0.584 (0.293–1.160) | 0.125 |
| Insurance* | ||||
| Uninsured | 1215 (2.5%) | 3 (3.2%) | ||
| Private | 13,276 (26.8%) | 30 (31.6%) | ||
| Medicaid or other governmental insurance | 4054 (8.2%) | 7 (7.4%) | NA | NA |
| Medicare | 21,041 (62.6%) | 55 (57.9%) | ||
| Facility type | ||||
| Community CP (ref) | 6140 (12.2%) | 5 (5.1%) | 1 | |
| Comprehensive community CP | 24,086 (47.8%) | 46 (46.9%) | 2.397 (0.952–6.036) | 0.064 |
| Academic/research CP | 13,123 (26.0%) | 36 (36.7%) | 3.320 (1.301–8.473) | 0.012 |
| Integrated network CP | 7032 (14.0%) | 11 (11.2%) | 1.966 (0.683–5.665) | 0.210 |
*
Insurance was not included in the multivariable model due to insignificant p value at univariate level.
**
p values reflect comparison with reference [indicated by “(ref)”]
CI, confidence interval; CP, cancer program; OR, odds ratio.